Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06232577

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

About this study

Primary Objectives:

The co-primary objectives of this study are as follows:

  • To determine differences in the initial OME prescribed upon discharge between each algorithm/model.
  • To determine OME usage by day 14 after hospital discharge.

Secondary Objectives:

Secondary objectives are as follows:

  • To determine rates of patients with zero OME upon discharge.
  • To determine rates of OME refill requests and completions at 15- and 30-days post-operation.
  • To determine number of unused or leftover pills at 15- and 30-days post- operation
  • To determine persistent opioid use at 30-days, 3-months, and 6-months post-operation
  • To elucidate patient, prescriber, and oncologic factors predictive of persistent opioid use
  • To assess quality of life using patient-reported outcomes at 30-days, 3-months, and 6-months post-operation.
  • To determine patient satisfaction with either prescribing model.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants ≥18 years of age
  • Participants undergoing any of the following abdominal surgeries on an elective basis at MD Anderson Cancer Center:
  • Open pancreatectomy
  • Open hepatectomy
  • Open resection of retroperitoneal sarcoma
  • Open nephrectomy
  • Open cytoreductive surgery (in ovarian cancer)
  • Participants with a planned inpatient admission of at least 48 hours after surgery
  • Opioid-naive patients who use less than or equal to 7.5 mg OME per day (on average) during the 30 days prior to consent
  • Participants able to understand and willing to sign an informed consent document
  • English and non-English-speaking participants

Exclusion criteria

  • Participants requiring non-elective (emergent or urgent) surgery will be excluded
  • Participants with a current or previous history of substance abuse disorder, including alcohol or drugs
  • Participants prescribed long-acting chronic pain medications
  • Participants using hydromorphone or fentanyl or under the care of a chronic pain specialist
  • Participants unable or unwilling to participate in follow-up study requirements (e.g., QOL surveys, opioid log)
  • Participants discharged on palliative or hospice care
  • Participants with a history of allergic reactions to opioids
  • Participants enrolled in any other opioid discharge protocol
  • Participants who are pregnant
  • Participants who are cognitively impaired

Treatment and study plan

Hydrocodone

Drug

Given by PO

Tramadol

Drug

Given by PO

Oxycodone

Drug

Given by PO

Other names: ETH-Oxydose™ [DSC], OxyContin®, OxyIR®, Roxicodone®

Primary outcomes

  1. Safety and adverse events (AEs)

    Time frame: Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jan 31, 2024
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.